We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Venous Leg Ulcers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01138436
First Posted: June 7, 2010
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Skingenix, Inc.
June 4, 2010
June 7, 2010
January 12, 2017
November 2010
October 2011   (Final data collection date for primary outcome measure)
Incidence of complete healing of the target ulcer within the 8-week treatment period. [ Time Frame: 8 week treatment period ]
Same as current
Complete list of historical versions of study NCT01138436 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Venous Leg Ulcers
A Phase II, Randomized, Controlled, Two-Center Pilot Study of the Safety and Efficacy of Topically Applied MEBO® Wound Ointment Compared to Standard of Care in Subjects With Venous Leg Ulcers
This is a Phase II, randomized, controlled, two-center pilot study designed to assess the safety and efficacy of MEBO in the treatment of 14 subjects with VLUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC (7 subjects per treatment arm).
To assess the safety and efficacy of MEBO in the treatment of 14 subjects with VLUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC (7 subjects per treatment arm).
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Ulcers
  • Drug: MEBO Wound Ointment (MEBO)
    Topical application once a day
    Other Name: MEBO
  • Procedure: Standard of Care
    Application of Profore multilayer compression bandage system
  • Experimental: MEBO Wound Ointment (MEBO)
    Topical application once a day
    Intervention: Drug: MEBO Wound Ointment (MEBO)
  • Active Comparator: Standard of Care
    Application of Profore multilayer compression bandage system
    Intervention: Procedure: Standard of Care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female ≥18 years of age.
  2. Able and willing to provide informed consent.
  3. Able and willing to comply with protocol visits and procedures.
  4. A full-thickness VLU that has been open continuously for ≥4 weeks and ≤1 year.

Exclusion Criteria:

  1. Ulcer of a non-venous hypertensive pathophysiology.
  2. Known or suspected allergy to any of the components of MEBO.
  3. Malignancy on target ulcer limb.
  4. Received another investigational device or drug within 30 days of enrollment.
  5. Non-compliance in the screening or run-in period.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01138436
MEBO-VSU-PII-001 v2.0
No
Not Provided
Plan to Share IPD: No
Skingenix, Inc.
Skingenix, Inc.
Not Provided
Study Chair: Robert Kirsner, MD, PhD University of Miami
Skingenix, Inc.
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP